COSIMO Cancer associated thrombosis - patient reported outcomes with rivaroxaban. A non-interventional study on patients changing to Xarelto® for treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in patients with active cancer

Study identification

• EU PAS number:
  EUPAS12608
• Study ID:
  33638
• Official title and acronym:
  COSIMO Cancer associated thrombosis - patient reported outcomes with rivaroxaban. A non-interventional study on patients changing to Xarelto® for treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in patients with active cancer
• DARWIN EU® study:
  No
• Study countries:
  Australia

  Belgium

  Canada

  Denmark

  France

  Germany

  Italy

  Netherlands

  Spain

  United Kingdom
• Study description:
  This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
• Study status:
  Finalised

Research institutions and networks

Institutions

Site in Germany

Multiple centres: 100 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual:02/03/2016

Study start date

Planned:31/10/2016

Actual:10/10/2016

Date of final study report

Planned:10/02/2020

Actual:10/02/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable